Home › Research › Drug development
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies
Loomis SJ, Miller R, Castrillo-Viguera C, Umans K, Cheng W, O'Gorman J, Hughes R, Budd Haeberlein S et al.. Neurology, 2023-12-28
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background and objectives Amyloid-related imaging abnormalities (ARIA) were the most common adverse events reported in the phase 3 ENGAGE and EMERGE trials of aducanumab, an anti-amyloid monoclonal antibody. APOE ε4 carrier status has been shown to increase risk of ARIA in prior trials of aducanumab and other anti-amyloid therapies; however, the remainder of the human genome has not been evaluated for ARIA risk factors. Therefore, we sought to determine in a hypothesis-free manner whether genetic variants beyond APOE influence risk of ARIA in aducanumab-treated patients.
What this study adds
Evidence grade: Moderate
This is a trial of 1,691 participants. This study performed genome-wide association studies of amyloid-related imaging abnormalities (ARIA) in participants in the aducanumab phase 3 ENGAGE and EMERGE trials, since APOE ε4 carrier status was already known to increase ARIA risk. Reported effect size: OR = 4.28; OR = 1.74; OR = 7.04-24.64.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Loomis, S. J., Miller, R., Castrillo-Viguera, C., Umans, K., Cheng, W., O'Gorman, J., et al. (2024). Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies. Neurology. https://doi.org/10.1212/wnl.0000000000207919
Vancouver
Loomis SJ, Miller R, Castrillo-Viguera C, Umans K, Cheng W, O'Gorman J, et al. Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies. Neurology. 2024. doi:10.1212/wnl.0000000000207919. PMID: 38165296.
BibTeX
@article{loomis2024-38165296,
author = {Loomis, S. J. and Miller, R. and Castrillo-Viguera, C. and Umans, K. and Cheng, W. and O'Gorman, J. and Hughes, R. and Budd Haeberlein, S. and others},
title = {{Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies}},
journal = {Neurology},
year = {2024},
doi = {10.1212/wnl.0000000000207919},
pmid = {38165296},
url = {https://doi.org/10.1212/wnl.0000000000207919}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- APOE ε4 carrier status has been shown to increase risk of ARIA in prior trials of aducanumab and other anti-amyloid therapies; however, the remainder of the human genome has not been evaluated for ARIA risk factors.
- Therefore, we sought to determine in a hypothesis-free manner whether genetic variants beyond APOE influence risk of ARIA in aducanumab-treated patients.
- Methods We performed genome-wide association studies (GWAS) of ARIA in participants in the ENGAGE and EMERGE trials.
- Participants had mild cognitive impairment due to Alzheimer disease or mild Alzheimer disease dementia and were amyloid-positive on PET scans.
Why it matters
This study performed genome-wide association studies of amyloid-related imaging abnormalities (ARIA) in participants in the aducanumab phase 3 ENGAGE and EMERGE trials, since APOE ε4 carrier status was already known to increase ARIA risk. It looks at genetic risk factors for a side effect of treatment, not at whether the drug cures or prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants1,691
- Effect sizeOR = 4.28; OR = 1.74; OR = 7.04-24.64
- Evidence strengthModerate
How this study scored 59/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,691 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 42 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 10.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 3 / 6 | Cited 6.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 6 other studies in this library |
| Still being cited | 2 / 4 | Cited 41 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Christopher D. Whelan: h-index 47 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Biogen (United States): institution h-index 495 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38165296) |
| Free to read | 2 / 2 | Free to read |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
6 studies in the alzhub library list this one in their references.
Related studies in Drug development from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.